Topical administration of the pan-Src kinase inhibitors, dasatinib and LCB 03-0110, prevents allergic contact dermatitis in mice

British Journal of Dermatology

Volumn 168, Issue 1, 2013, Pages 112-119

  Jung, S H ^a,b   Sun, X ^a   Ryu, W S ^b   Yang, Beom Seok ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON C; ANTIALLERGIC AGENT; DASATINIB; HEMATOXYLIN; INTERLEUKIN 1BETA; LCB 03 0110; LCB 030110; OXAZOLONE; PROTEIN TYROSINE KINASE INHIBITOR; TACROLIMUS; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; FEMALE; HAIRLESS MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ALLERGY; SKIN ATROPHY; SKINFOLD THICKNESS; STAINING; TREATMENT DURATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; AMINOPYRIDINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ATROPHY; DERMATITIS, ALLERGIC CONTACT; DRUG EVALUATION; FEMALE; MICE; MICE, HAIRLESS; MICE, INBRED BALB C; OXAZOLONE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SKIN; THIAZOLES; THIOPHENES;

EID: 84872868955     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12069     Document Type: Article

References (51)

1. Thyssen JP, Menne T, Schnuch A, et al. Acceptable risk of contact allergy in the general population assessed by CE-DUR-a method to detect and categorize contact allergy epidemics based on patient data. Regul Toxicol Pharmacol 2009; 54: 183-7.
2. Schnuch A, Uter W, Geier J, Gefeller O,. Epidemiology of contact allergy: an estimation of morbidity employing the clinical epidemiology and drug-utilization research (CE-DUR) approach. Contact Dermatitis 2002; 47: 32-39.
3. Christensen AD, Haase C,. Immunological mechanisms of contact hypersensitivity in mice. APMIS 2012; 120: 1-27.
4. Cumberbatch M, Dearman RJ, Kimber I,. Langerhans cells require signals from both tumour necrosis factor-alpha and interleukin-1 beta for migration. Immunology 1997; 92: 388-95.
5. Enk AH, Angeloni VL, Udey MC, Katz SI,. An essential role for Langerhans cell-derived IL-1 beta in the initiation of primary immune responses in skin. J Immunol 1993; 150: 3698-704.
6. Bennett CL, Noordegraaf M, Martina CAE, Clausen BE,. Langerhans cells are required for efficient presentation of topically applied hapten to T cells. J Immunol 2007; 179: 6830-5.
7. Enk AH, Katz SI,. Early molecular events in the induction phase of contact sensitivity. Proc Natl Acad Sci USA 1992; 89: 1398-402.
8. Bour H, Peyron E, Gaucherand M, et al. Major histocompatibility complex class I-restricted CD8+ T cells and class II-restricted CD4+ T cells, respectively, mediate and regulate contact sensitivity to dinitrofluorobenzene. Eur J Immunol 1995; 25: 3006-10.
9. Gocinski BL, Tigelaar RE,. Roles of CD4+ and CD8+ T cells in murine contact sensitivity revealed by in vivo monoclonal antibody depletion. J Immunol 1990; 144: 4121-8.
10. Pickard C, Smith AM, Cooper H, et al. Investigation of mechanisms underlying the T-cell response to the hapten 2,4-dinitrochlorobenzene. J Invest Dermatol 2007; 127: 630-7.
11. Kish DD, Li X, Fairchild RL,. CD8 T cells producing IL-17 and IFN-gamma initiate the innate immune response required for responses to antigen skin challenge. J Immunol 2009; 182: 5949-59.
12. He D, Wu L, Kim HK, et al. IL-17 and IFN-gamma mediate the elicitation of contact hypersensitivity responses by different mechanisms and both are required for optimal responses. J Immunol 2009; 183: 1463-70.
13. He D, Wu L, Kim HK, et al. CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J Immunol 2006; 177: 6852-8.
14. Saulnier M, Huang S, Aguet M, Ryffel B,. Role of interferon-[gamma] in contact hypersensitivity assessed in interferon-[gamma] receptor-deficient mice. Toxicology 1995; 102: 301-12.
15. Usatine RP, Riojas M,. Diagnosis and management of contact dermatitis. Am Fam Physician 2010; 82: 249-55.
16. Lauerma AI, Maibach HI, Granlund H, et al. Inhibition of contact allergy reactions by topical FK506. Lancet 1992; 340: 556.
17. Lazarous MC, Kerdel FA,. Topical tacrolimus Protopic. Drugs Today (Barc) 2002; 38: 7-15.
18. Wolff K, Stuetz A,. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004; 5: 643-55.
19. Fisher DA,. Adverse effects of topical corticosteroid use. West J Med 1995; 162: 123-6.
20. Schoepe S, Schacke H, May E, Asadullah K,. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 2006; 15: 406-20.
21. Niwa Y, Terashima T, Sumi H,. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003; 149: 960-7.
22. Ring J, Möhrenschlager M, Henkel V,. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008; 31: 185-98.
23. Das J, Chen P, Norris D, et al. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2- methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 2006; 49: 6819-32.
24. Steinberg M,. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007; 29: 2289-308.
25. Sun X, Phan TN, Jung SH, et al. LCB 03-0110, a novel pan-discoidin domain receptor/c-Src family tyrosine kinase inhibitor, suppresses scar formation by inhibiting fibroblast and macrophage activation. J Pharmacol Exp Ther 2012; 340: 510-9.
26. Rix U, Hantschel O, Dürnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055-63.
27. Li J, Rix U, Fang B, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 2010; 6: 291-9.
28. Bradshaw JM,. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal 2010; 22: 1175-84.
29. Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007; 104: 13283-8.
30. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366-77.
31. Fraser CK, Lousberg EL, Kumar R, et al. Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. Exp Hematol 2009; 37: 1435-44.
32. Fujii Y, Takeuchi H, Tanaka K, et al. Effects of FK506 (tacrolimus hydrate) on chronic oxazolone-induced dermatitis in rats. Eur J Pharmacol 2002; 456: 115-21.
33. Gnoni A, Marech I, Silvestris N, et al. Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets 2011; 12: 563-78.
34. Homsi J, Cubitt CL, Zhang S, et al. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res 2009; 19: 167-75.
35. Sumen C, Mempel TR, Mazo IB, von Andrian UH,. Intravital microscopy: visualizing immunity in context. Immunity 2004; 21: 315-29.
36. Barker JN,. Adhesion molecules in cutaneous inflammation. Ciba Found Symp 1995; 189: 91-106.
37. Petersen TK, Sørensen P,. Translational dermatology in drug discovery: perspectives for integrating humanized xenograft models and experimental clinical studies. Drug Discov Today 2008; 13: 240-6.
38. Schoepe S, Schacke H, Asadullah K,. Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. Dermatoendocrinology 2011; 3: 175-9.
39. Kirby JD, Munro DD,. Steroid-induced atrophy in an animal and human model. Br J Dermatol 1976; 12: 111-9.
40. Young JM, Yoxall BE, Wagner BM,. Corticosteroid-induced dermal atrophy in the rat. J Invest Dermatol 1977; 69: 458-62.
41. Herold MJ, McPherson KG, Reichardt HM,. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 2006; 63: 60-72.
42. Schreiber SL,. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991; 251: 283-7.
43. Salmond RJ, Filby A, Qureshi I, et al. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev 2009; 228: 9-22.
44. Molina TJ, Kishihara K, Siderovski DP, et al. Profound block in thymocyte development in mice lacking p56lck. Nature 1992; 357: 161-3.
45. Appleby MW, Gross JA, Cooke MP, et al. Defective T cell receptor signaling in mice lacking the thymic isoform of p59fyn. Cell 1992; 70: 751-63.
46. Tuckermann JP, Kleiman A, Moriggl R, et al. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest 2007; 117: 1381-90.
47. Cohen J,. The immunopathogenesis of sepsis. Nature 2002; 420: 885-91.
48. Suen PW, Ilic D, Caveggion E, et al. Impaired integrin-mediated signal transduction, altered cytoskeletal structure and reduced motility in Hck/Fgr deficient macrophages. J Cell Sci 1999; 112: 4067-78.
49. Berton G, Fumagalli L, Laudanna C, Sorio C,. Beta 2 integrin dependent protein tyrosine phosphorylation and activation of the FGR protein tyrosine kinase in human neutrophils. J Cell Biol 1994; 126: 1111-21.
50. Yan SR, Fumagalli L, Berton G,. Activation of p58c-fgr and p53/56lyn in adherent human neutrophils: evidence for a role of divalent cations in regulating neutrophil adhesion and protein tyrosine kinase activities. J Inflamm 1995; 45: 297-311.
51. Mocsai A, Ligeti E, Lowell CA, Berton G,. Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck. J Immunol 1999; 162: 1120-6.